About Actin, cytoplasmic 1
Actin, cytoplasmic 1 (ACTB) is a protein
from Homo sapiens identified by UniProt accession
P60709, 375 residues long.
MolForge cross-references it against 0 known binders and
1,301 disease associations.
Target properties
| Protein name | Actin, cytoplasmic 1 |
|---|
| UniProt accession | P60709 |
|---|
| Gene | ACTB |
|---|
| Organism | Homo sapiens |
|---|
| Length | 375 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (1301)
Diseases linked to this target (Open Targets).
- Baraitser-Winter syndrome 1 · score 0.82
- Baraitser-Winter syndrome · score 0.78
- developmental malformations-deafness-dystonia syndrome · score 0.74
- Developmental malformations - deafness - dystonia · score 0.68
- cancer · score 0.62
- genetic disorder · score 0.53
- Noonan syndrome · score 0.53
- hypertrophic cardiomyopathy · score 0.51
- Costello syndrome · score 0.50
- Intellectual disability · score 0.47
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P60709-F1 | alphafold | PREDICTED | 95.20 | — |
Amino-acid sequence (375 residues)
MDDDIAALVV DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE HPVLLTEAPL NPKANREKMT QIMFETFNTP AMYVAIQAVL SLYASGRTTG IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF TTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS GGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS TFQQMWISKQ EYDESGPSIV HRKCF
Explore Actin, cytoplasmic 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets